Engineers Gate Manager’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.52M | Sell |
3,066
-10,752
| -78% | -$4.77M | 0.02% | 837 |
|
|
2026
Q1 | $6.17M | Buy |
13,818
+9,154
| +196% | +$4.27M | 0.08% | 316 |
|
|
2025
Q4 | $2.11M | Sell |
4,664
-10,179
| -69% | -$4.39M | 0.03% | 686 |
|
|
2025
Q3 | $5.81M | Buy |
+14,843
| New | +$6.2M | 0.07% | 352 |
|
|
2025
Q1 | – | Sell |
-11,599
| Closed | -$4.67M | – | 2611 |
|
|
2024
Q4 | $4.67M | Buy |
+11,599
| New | +$5.38M | 0.08% | 325 |
|
|
2024
Q3 | – | Sell |
-13,386
| Closed | -$6.27M | – | 2435 |
|
|
2024
Q2 | $6.27M | Buy |
13,386
+881
| +7% | +$382K | 0.14% | 198 |
|
|
2024
Q1 | $5.23M | Buy |
12,505
+4,886
| +64% | +$2.07M | 0.14% | 191 |
|
|
2023
Q4 | $3.1M | Sell |
7,619
-1,096
| -13% | -$405K | 0.09% | 314 |
|
|
2023
Q3 | $3.03M | Buy |
8,715
+5,422
| +165% | +$1.9M | 0.11% | 229 |
|
|
2023
Q2 | $1.16M | Buy |
3,293
+779
| +31% | +$262K | 0.04% | 610 |
|
|
2023
Q1 | $792K | Sell |
2,514
-27,783
| -92% | -$8.33M | 0.03% | 753 |
|
|
2022
Q4 | $8.75M | Buy |
30,297
+27,959
| +1,196% | +$8.52M | 0.53% | 12 |
|
|
2022
Q3 | $677K | Sell |
2,338
-2,773
| -54% | -$798K | 0.04% | 619 |
|
|
2022
Q2 | $1.44M | Sell |
5,111
-2,153
| -30% | -$576K | 0.05% | 491 |
|
|
2022
Q1 | $1.9M | Sell |
7,264
-2,678
| -27% | -$636K | 0.07% | 350 |
|
|
2021
Q4 | $2.18M | Sell |
9,942
-33,802
| -77% | -$6.57M | 0.1% | 254 |
|
|
2021
Q3 | $7.93M | Buy |
43,744
+16,851
| +63% | +$3.29M | 0.45% | 22 |
|
|
2021
Q2 | $5.42M | Buy |
26,893
+24,300
| +937% | +$5.08M | 0.35% | 42 |
|
|
2021
Q1 | $557K | Buy |
2,593
+14
| +0.5% | +$3.08K | 0.03% | 925 |
|
|
2020
Q4 | $610K | Sell |
2,579
-9,241
| -78% | -$2.12M | 0.03% | 859 |
|
|
2020
Q3 | $3.22M | Buy |
11,820
+9,410
| +390% | +$2.6M | 0.15% | 164 |
|
|
2020
Q2 | $700K | Sell |
2,410
-18
| -0.7% | -$4.88K | 0.04% | 777 |
|
|
2020
Q1 | $578K | Sell |
2,428
-12,957
| -84% | -$2.97M | 0.04% | 686 |
|
|
2019
Q4 | $3.37M | Buy |
15,385
+11,654
| +312% | +$2.36M | 0.15% | 182 |
|
|
2019
Q3 | $632K | Sell |
3,731
-11,172
| -75% | -$1.98M | 0.03% | 689 |
|
|
2019
Q2 | $2.73M | Buy |
+14,903
| New | +$2.61M | 0.15% | 208 |
|
|
2017
Q2 | – | Sell |
-4,300
| Closed | -$470K | – | 814 |
|
|
2017
Q1 | $470K | Buy |
+4,300
| New | +$379K | 0.05% | 455 |
|
|
2016
Q2 | – | Sell |
-12,638
| Closed | -$1M | – | 844 |
|
|
2016
Q1 | $1M | Buy |
+12,638
| New | +$1.14M | 0.08% | 386 |
|
|
2015
Q3 | – | Sell |
-2,100
| Closed | -$259K | – | 974 |
|
|
2015
Q2 | $259K | Buy |
2,100
+144
| +7% | +$18.1K | 0.03% | 839 |
|
|
2015
Q1 | $231K | Buy |
+1,956
| New | +$234K | 0.03% | 803 |
|
Other funds holding VRTX
Engineers Gate Manager's VRTX Position: Q2 2026 in Review
Engineers Gate Manager reduced its Vertex Pharmaceuticals (VRTX) stake by 78% in Q2 2026, selling an estimated $4.77M and leaving 3,066 shares worth $1.52M. The position accounts for 0.02% of the portfolio, ranked #837.
Engineers Gate Manager first reported a position in VRTX in Q1 2015 and has held it in 30 quarters since. The position peaked at $8.75M in Q4 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Engineers Gate Manager held 3,066 shares of Vertex Pharmaceuticals worth $1.52M as of Q2 2026.
- Engineers Gate Manager sold 10,752 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.77M.
- Vertex Pharmaceuticals made up 0.02% of Engineers Gate Manager's portfolio in Q2 2026, its #837 holding.
- Engineers Gate Manager first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 30 quarters since.
- Engineers Gate Manager's Vertex Pharmaceuticals position peaked at $8.75M in Q4 2022.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.